Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy

Yuting Ma; Sandy Adjemian; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer

doi:10.4161/onci.27663

Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy

Yuting Ma, Sandy Adjemian, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

Depending on tumor type, stage and immunological contexture, the inhibition of chemokines or their receptors may yield positive or deleterious effects on disease progression. We have recently demonstrated in several murine models of anthracycline-based chemotherapy that the inhibition of chemokine (C-C motif) ligand 2 (CCL2) or chemokine (C-C motif) receptor 2 (CCR2) may impair the elicitation of anticancer immune responses that contribute to therapeutic success.

Original language	English
Article number	e27663
Journal	OncoImmunology
Volume	3
Issue number	1
DOIs	https://doi.org/10.4161/onci.27663
Publication status	Published - 1 Jan 2014

Keywords

ATP
Autophagy
Cancer stem cells
Immunogenic cell death
Immunosurveillance
T lymphocytes
γδ

Access to Document

10.4161/onci.27663

Cite this

@article{4e0c0b002668444cb201c6fa5f496151,

title = "Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy",

abstract = "Depending on tumor type, stage and immunological contexture, the inhibition of chemokines or their receptors may yield positive or deleterious effects on disease progression. We have recently demonstrated in several murine models of anthracycline-based chemotherapy that the inhibition of chemokine (C-C motif) ligand 2 (CCL2) or chemokine (C-C motif) receptor 2 (CCR2) may impair the elicitation of anticancer immune responses that contribute to therapeutic success.",

keywords = "ATP, Autophagy, Cancer stem cells, Immunogenic cell death, Immunosurveillance, T lymphocytes, γδ",

author = "Yuting Ma and Sandy Adjemian and Lorenzo Galluzzi and Laurence Zitvogel and Guido Kroemer",

year = "2014",

month = jan,

day = "1",

doi = "10.4161/onci.27663",

language = "English",

volume = "3",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy

AU - Ma, Yuting

AU - Adjemian, Sandy

AU - Galluzzi, Lorenzo

AU - Zitvogel, Laurence

AU - Kroemer, Guido

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Depending on tumor type, stage and immunological contexture, the inhibition of chemokines or their receptors may yield positive or deleterious effects on disease progression. We have recently demonstrated in several murine models of anthracycline-based chemotherapy that the inhibition of chemokine (C-C motif) ligand 2 (CCL2) or chemokine (C-C motif) receptor 2 (CCR2) may impair the elicitation of anticancer immune responses that contribute to therapeutic success.

AB - Depending on tumor type, stage and immunological contexture, the inhibition of chemokines or their receptors may yield positive or deleterious effects on disease progression. We have recently demonstrated in several murine models of anthracycline-based chemotherapy that the inhibition of chemokine (C-C motif) ligand 2 (CCL2) or chemokine (C-C motif) receptor 2 (CCR2) may impair the elicitation of anticancer immune responses that contribute to therapeutic success.

KW - ATP

KW - Autophagy

KW - Cancer stem cells

KW - Immunogenic cell death

KW - Immunosurveillance

KW - T lymphocytes

KW - γδ

UR - http://www.scopus.com/inward/record.url?scp=84899082313&partnerID=8YFLogxK

U2 - 10.4161/onci.27663

DO - 10.4161/onci.27663

M3 - Article

AN - SCOPUS:84899082313

SN - 2162-4011

VL - 3

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - e27663

ER -

Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy

Abstract

Keywords

Access to Document

Other files and links

Cite this